DetailsCategory: Proteins and PeptidesPublished on Thursday, 09 January 2020 12:06Hits: 265

Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model

MENLO PARK, CA, USA I January 08, 2020 I CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today announced the discovery of a series of novel mitochondrial peptide analogs with potent in vitro activity as selective inhibitors of C-X-C Chemokine Receptor Type 4 (CXCR4) and with preliminary in vivo efficacy in a mouse model of melanoma, including substantial reduction in tumor growth as compared to control animals. CXCR4 is a key regulatory receptor involved in tumor growth, invasion, angiogenesis, metastasis, and resistance to therapy.

This new discovery offers the potential to develop novel therapeutics for difficult-to-treat cancers, based on peptides encoded in the mitochondrial genome, said Ken Cundy, Ph.D., CohBars Chief Scientific Officer. Inhibition of this key regulatory pathway is potentially applicable to a wide range of cancers, as well as orphan indications where CXCR4 signaling is dysregulated.

Novel peptide analogs of a mitochondrially encoded peptide (MBT5) demonstrated potent and selective inhibition of human CXCR4 receptor in cell-based assays, with IC50 values in the low nanomolar concentration range. In a difficult-to-treat in vivo mouse model of melanoma, the B16F10 syngeneic tumor model, the combination of an analog of MBT5 administered subcutaneously with the chemotherapeutic temozolomide showed enhanced antitumor activity, reducing tumor growth after 11 days by 61% compared to control animals. The reduction in tumor growth produced by the combination exceeded the effect of either temozolomide used as a single agent, which reduced tumor growth by 38% compared to control, or the murine checkpoint inhibitor anti-PD-1 antibody, which had no effect on tumor growth in this model.

CohBar plans to further explore the efficacy of this new family of peptides in additional animal models with the goal of identifying a new clinical development MBT candidate.

These new data further expand our understanding of the broad regulatory influence exerted by mitochondria and the therapeutic potential of analogs of peptides encoded in mitochondrial DNA, said Steve Engle, CohBar CEO. We are just beginning to scratch the surface of this previously untapped field.

CXCR4 is overexpressed in more than 75% of cancers and high levels of the receptor are associated with poor survival prognosis. Inhibition of the CXCR4 receptor has been shown to mobilize immune cells, enhance the effects of chemotherapy and immunotherapy in various cancers, and reduce the development of metastatic tumors by blocking the ability of tumor cells to evade immune surveillance. CXCR4 also regulates the homing and retention of hematopoietic stem cells and malignant cells in the bone marrow.

Further details of these new studies will be available on the CohBar website at http://www.cohbar.com.

About CohBar

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBars founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial-derived peptides. CohBars efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, type 2 diabetes, and cardiovascular and neurodegenerative diseases. The companys lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial that includes an evaluation of biological activity relevant to NASH and obesity.

For additional company information, please visit http://www.cohbar.com.

SOURCE: CohBar

The rest is here:
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis | Proteins and Peptides | News Channels -...

Bone Marrow Stem Cells Comments Off on CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis | Proteins and Peptides | News Channels -… | January 10th, 2020

When a person's immune system is impaired by a genetic disease, a bone-marrow transplant can be a powerful therapeutic tool, but with a major downside: during the first few months the recipient's defenses against viruses are severely weakened. The slightest infection can lead to a hospital trip.

A still-experimental type of treatment known as T-cell therapy aims to assist during this vulnerable period -- the months during which the body is rebuilding its natural defenses. After two decades of clinical trials, the technology has been refined, and is being used to treat more and more patients, many of them children.

A boy named Johan is one of them.

Today he is a mischievous, smiling toddler with a thick shock of light-brown hair, who never tires, playfully tormenting the family's puppy, Henry. There is no sign of the three-year-long medical and emotional roller-coaster ride he and his family, who live in an affluent Washington suburb, have been on.

The first traumatic surprise came with the results of a pregnancy test: Johan was not planned.

"That was a huge shock. I cried," said his mother, 39-year-old Maren Chamorro.

She had known since childhood that she carried a gene that can be fatal in a child's first 10 years, chronic granulomatous disease (CGD). Her brother died of it at the age of seven. The inexorable laws of genetics meant that Maren had a one in four chance of transmitting it to her child.

For their first children, she and her husband Ricardo had chosen in-vitro fertilization, allowing the embryos to be genetically tested before implantation.

Their twins Thomas and Joanna were born -- both disease-free -- seven and a half years ago. But in Johan's case, a post-birth genetic test quickly confirmed the worst: he had CGD.

After conferring with experts at Children's National Hospital in Washington, the couple took one of the most important decisions of their lives: Johan would receive a bone-marrow transplant, a risky procedure but one that would give him a chance of a cure.

"Obviously, the fact that Maren had lost a sibling at a young age from the disease played a big role," Ricardo confided.

Bone marrow, the spongy tissue inside bones, serves as the body's "factory" for the production of blood cells -- both red and white.

Johan's white blood cells were incapable of fighting off bacteria and fungal infections. A simple bacterial infection, of negligible concern in a healthy child, could spread out of control in his young body.

Luckily, Johan's brother Thomas, six years old at the time, was a perfect match. In April 2018, doctors first "cleansed" Johan's marrow using chemotherapy. They then took a small amount of marrow from Thomas's hip bones using a long, thin needle.

From that sample they extracted "supercells," as Thomas calls them -- stem cells, which they reinjected into Johan's veins. Those cells would eventually settle in his bone marrow -- and begin producing normal white blood cells.

The second step was preventive cell therapy, under an experimental program led by immunologist Michael Keller at Children's National Hospital.

The part of the immune system that protects against bacteria can be rebuilt in only a matter of weeks; but for viruses, the natural process takes at least three months.

From Thomas's blood, doctors extracted specialized white blood cells -- T-cells -- that had already encountered six viruses.

Keller grew them for 10 days in an incubator, creating an army of hundreds of millions of those specialized T-cells. The result: a fluffy white substance contained in a small glass vial.

Those T-cells were then injected into Johan's veins, immediately conferring protection against the six viruses.

"He has his brother's immune system," said Keller, an assistant professor at Children's National.

Johan's mother confirmed as much: today, when Thomas and Johan catch a cold, they have the same symptoms, and for nearly the same amount of time.

"I think it's pretty cool to have immunity from your big brother," Maren Chamorro said.

This therapeutic approach -- boosting the body's immune system using cells from a donor or one's own genetically modified cells -- is known as immunotherapy.

Its main use so far has been against cancer, but Keller hopes it will soon become available against viruses for patients, like Johan, who suffer from depressed immune systems.

The chief obstacles to that happening are the complexity of the process and the costs, which can run to many thousands of dollars. These factors currently restrict the procedure to some 30 medical centers in the United States.

For Johan, a year and a half after his bone marrow transplant, everything points to a complete success.

"It's neat to see him processing things, and especially play outside in the mud," his mother said. "You know, what a gift!"

Her only concern now is the same as any mother would have -- that when her son does fall ill, others in the family might catch the same bug.

Read the rest here:
The 'supercells' that cured an infant's grave genetic illness - Japan Today

Bone Marrow Stem Cells Comments Off on The ‘supercells’ that cured an infant’s grave genetic illness – Japan Today | January 10th, 2020

Daily life can be excruciatingly painful and tiring for a West Bridgford mum suffering with a lifelong inherited blood disease.

Oyesola Oni, 37, was born with sickle cell disease and has to have eight pints of blood transfused into her body every six weeks at Nottingham City Hospital.

Sickle cell can cause serious and potentially fatal complications such as organ damage, stroke, death to bone tissue and acute chest syndrome.

People with sickle cell disease produce "unusually shaped" red blood cells that can cause problems because they do not live as long as healthy blood cells. They can also block blood vessels.

If both parents have the gene that affects red blood cells, there's a one in four chance of each child they have being born with the disease.

I mainly get crisis pains in my ribs, legs, hips, my back and my lower abdomen. You cant describe the pain," said Oye, of West Bridgford.

"Its like something stabbing me, at other times its like something crushing my bones. Its excruciating."

The only cure for sickle cell disease is astem cell or bone marrow transplant,but they're not done very often because of the risks involved.

Her story comes as the NHS launch a call for more men to donate blood in 2020 because of a "serious imbalance" in the gender of new donors.

The mum has regular red cell transfusions for sickle cell disease after several years of her condition getting worse.

Having a secure supply of blood is particularly important for people like Mrs Oni, who receive many transfusions over their lives.

The mum to daughter Ade, 12, who does not have sickle cell, said people who donate the blood that she receives are "heroes that dont wear capes".

They give blood to someone they dont know its amazing, very selfless. Its an extraordinary thing to do and I hope more men start donating blood in the New Year," she added.

"Having the transfusions gives me so much more energy, keeps me out of hospital and allows me to spend more time with my family."

The mum said she hopes to return to work as in customer services thanks to the continued transfusions.

During 2019, 43 percent of the new donors at Nottingham Donor Centre were men.

Until the end of November, 1,203 women started donating blood in Nottingham but only 898 men.

The NHS said this is a concern because men have higher iron levels and only mens blood can be used for some transfusions and products.

Without more men starting to give blood, blood stocks will come under increasing pressure in future years, the NHS has warned.

Mike Stredder, the head of donor recruitment for NHS Blood and Transplant, added: All our donors are amazing. But we need more men to start donating blood in Nottingham during the New Year.

"Mens blood can be used in extraordinary, lifesaving ways, but we dont have enough new male donors coming forward.

"This is not about recruiting as many donors as possible its about getting the right gender mix.

If you cant find an appointment right away dont worry your blood will do extraordinary things if you donate in a few weeks instead."

Read more here:
Mum's 'excruciating' battle with lifelong disease that requires regular blood transfusions - Nottinghamshire Live

Bone Marrow Stem Cells Comments Off on Mum’s ‘excruciating’ battle with lifelong disease that requires regular blood transfusions – Nottinghamshire Live | January 10th, 2020

As humans continue to pump more and more carbon dioxide into the atmosphere, concerns about global warming and climate change continue to grow. But what if that CO2 could be turned into a source of energy? One startup in Kyoto has developed cutting-edge nano-materials that could trap atmospheric CO2 and harness it as a power source. Its one way that Japans ancient capital is harnessing its large scientific and biomedical potential to address environmental and social problems.

Panning for invisible gold

Porous coordination polymers can be a form of carbon-capture technology, says discoverer Susumu Kitagawa, second from left, with (left to right) Atomis CTO Masakazu Higuchi, CEO Daisuke Asari, R&D officer Kenji Sumida, and COO Dai Kataoka.

Atomis is a new materials company that was spun off from Kyoto University. Founded in 2015 following government-supported research, its business is based on studies led by Susumu Kitagawa, a professor in the universitys Institute for Advanced Study. Its core technology is the production of materials comprising extremely small void spaces that can trap gases, including CO2. A breakthrough discovery in 1997 by Kitagawa, who has been considered a contender for the Nobel Prize in Chemistry, these porous coordination polymers (PCPs, aka metal-organic frameworks) have enormous potential as tools to precisely control gases.

Humans have used the principle behind PCPs for thousands of years. They work the same way that a hunk of charcoal traps ambient odor molecules in its large surface area, but PCPs are many times more powerful. To the naked eye, PCPs look like powders, pellets or granules of various colors, shapes and sizes. But if you were to zoom in, you would see that PCPs are sponge-like materials with pores the size of a nanometer, or one billionth of a meter. They can be designed as scaffoldlike 3D structures from metals and organic ligands, and can be used for storage, separation and conversion of molecules.

These materials are unique in that we can design the shapes and chemical properties of the pores to suit specific applications, and some of the materials have flexible structures, which can potentially provide them with even more advanced features, says Daisuke Asari, president and CEO of Atomis. The company is basically the only business in Japan working with these materials in an industrial context. Collaborating with Kitagawa is a big advantage over foreign rivals, adds Kenji Sumida, executive officer for R&D.

One challenge related to these nanomaterials is that its difficult and costly to produce more than a few kilograms per day. Massively scaling production so that PCPs can be used to fight climate change is one reason that Atomis was founded, says Atomis founder and CTO Masakazu Higuchi, one of Kitagawas collaborators. The firm is developing solid-state techniques and making capital investments to increase PCP production capacity. Meanwhile, Atomis has developed products that harness the groundbreaking potential of PCPs, including Cubitan, a compact and lightweight gas cylinder for industrial and consumer use packed with smart features, such as the ability to notify users when the amount of reserve gas becomes low.

When viewed without special equipment, PCPs look like powders, pellets or granules of various colors, shapes and sizes, but they are sponge-like materials with countless pores the size of a nanometer.

Kitagawa has his sights on the bigger picture. He believes PCPs can be used as a form of carbon-capture technology, allowing the synthesis of methanol, an energy source. Thats why he calls CO2 invisible gold.

In ancient China, Taoist mystics were said to live in the mountains and survive simply on mist, which consists of water, oxygen and CO2, says Kitagawa. They were taking something valueless and using it for energy. Similarly, PCPs can control gases that humans cannot use and turn them into something beneficial, for instance absorbing CO2 in the air and turning into methanol and other hydrocarbon materials.

Building a regenerative medicine Silicon Valley

Atomis is one of many science startups in Kyoto that have benefitted from collaborative research between industry and government. Its part of a growing startup industry in Japan, where total funding for new companies reached a record high of 388 billion yen in 2018, up from 64.5 billion yen in 2012, according to Japan Venture Research. One driver for this expansion is science and technology discoveries.

While it may be known for its traditional culture, Kyoto has a strong pedigree in scientific research. It is home to 38 universities and about 150,000 students, which form a large pool of institutional knowledge, experience and talent. Many recent Nobel laureates either graduated from or taught at Kyoto University, including professors Tasuku Honjo and Shinya Yamanaka, who won the Nobel Prize for Physiology or Medicine in 2018 and 2012, respectively. Working on discoveries by Yamanaka, Megakaryon has become a world leader in creating artificial blood platelets made from synthetic stem cells.Theres also a large group of high-tech companies that have carved out niches for themselves internationally.

Kyoto is a unique city in that it has an independent spirit that is similar to the U.S. West Coast, says Eiichi Yamaguchi, a professor at Kyoto University who has founded four companies.

Kyoto companies like Murata Manufacturing, Horiba, Shimadzu, and Kyocera have a global market and theyre competing with China, says Eiichi Yamaguchi, a professor at Kyoto University who has founded four companies. Thats the difference with companies in Tokyo, which are more domestically oriented.

Yamaguchi has authored several books on innovation, and says there is a growing awareness of the importance of collaborative research and entrepreneurship in Kyoto. He cites a recently formed cooperative group of seven university chairpersons and presidents from leading materials and biosciences companies that meets to discuss issues such as fostering new technologies, for instance building high-speed hydrogen fueling systems.

Kyoto is a unique city in that it has an independent spirit that is similar to the U.S. West Coast, says Yamaguchi. Kyoto is only a fraction of the size of Tokyo, but if you take a stand here, people will pay attention.

Another group that is promoting local high-tech business is Innovation Hub Kyoto. Its an open innovation facility based in the Kyoto University Graduate School of Medicine aimed at commercializing research from the university. Steps away from Kyotos historic Kamo River, its geared to researchers, investors, startups, and established companies working in the field of medical innovation including device development and drug discovery. This is where Japanese researchers are trying to build a Silicon Valley of regenerative medicine.

Tenants at Innovation Hub Kyoto can use this wet lab for research.

Part of the Kyoto University Medical Science and Business Liaison Organization, the hub was established about 15 years ago and opened a new building in 2017 with the support of the Ministry of Education, Culture, Sports, Science and Technology. The structure has a variety of labs, including ones meeting biosafety level P2 and for animal experiments.

Its tough for startups in Japan to access to animal laboratories like the one we have, says hub leader Yutaka Teranishi, a professor in the Graduate School of Medicine who estimates that some 50% of university researchers want to work with industry, up from 10% a few years ago. Were focused on university startups because its very difficult for them to develop drugs from just an alliance between companies and universities.

About 28 companies are tenants at Innovation Hub Kyoto. They include major brands such as Shimadzu and Nippon Boehringer Ingelheim as well as younger businesses. One is AFI, founded in 2013 and focused on fluid, electric filtering and sorting (FES) technology that can be used for applications ranging from food safety inspections to rapid diagnosis of disease to regenerative medicine.

Tomoko Bylund heads the Japan office of CELLINK, a Swedish bioprinting and bioink company that is a tenant at Innovation Hub Kyoto.

Another tenant is CELLINK, a Swedish bioprinting and bioink company headed in the Japan by Tomoko Bylund. Using its products, researchers can print body parts with human cells for drug and cosmetics testing. In 2019, the first 3D print of a human cornea in the U.S. was accomplished with the companys BIO X Bioprinter.

iHeart Japan is also a tenant. It was established in 2013 as a regenerative medicine business and is aiming to address a major shortage in the Japanese medical system: only about 40 out of 200,000 people on national waiting lists can receive donor hearts every year. The company is developing innovative medical products such as multi-layered cardiac cell sheets derived from synthetic stem cells. The Hub basis its success in fostering companies on its diversity and the business environment in Kyoto.

We have people from different backgrounds here who are exchanging cultures and experimental results, and this diversity is powering innovation here, says Teranishi. There are many traditional industries in Kyoto, and though people say its a conservative city, these companies have survived because theyre open to new technologies and have taken the time to choose which ones can help them. Thats how this city and its businesses have lasted for more than 1,000 years.

Diversity is powering innovation here, says Yutaka Teranishi, center, head of Innovation Hub Kyoto, with Kyoto University professor Hirokazu Yamamoto, left, and Graduate School of Medicine lecturer Taro Yamaguchi, right.

To learn more about Atomis, click here.

To learn more about Innovation Hub Kyoto, click here.

Visit link:
How Kyoto Is Rebuilding Itself As A Nanotech And Regenerative Medicine Powerhouse - Forbes

Cardiac Stem Cells Comments Off on How Kyoto Is Rebuilding Itself As A Nanotech And Regenerative Medicine Powerhouse – Forbes | January 10th, 2020

LOS ANGELES (PRWEB) January 09, 2020

DOXYVA is a validated circulatory and nerve stimulant. The system was used by Prof. Puruhito for CO transdermal delivery, which has been shown to produce higher oxygen unloading by hemoglobin, thereby increasing oxygen-rich blood flow in the local microcirculatory system. This improved dermal microcirculation leads, in turn, to enhanced wound healing.

The American Diabetes Association standards of care for DFUs refer to microvascular complications and their treatment via improvements in microcirculation; therefore, Prof. Puruhitos team set out to test CO transdermal delivery via DOXYVA in their patients. They have been gathering data since 2015, which led to the following results.

During the course of a 5-day treatment, O saturation increased in patients treated with transdermal CO in comparison to controls (15 patients/group) over the whole measurement range (up to 120 minutes post application). Moreover, a consistent heart rate decrease was found in patients undergoing transdermal CO treatment. Furthermore, the perfusion index (PI) showed an upwards tendency in the treatment group, whereas it remained stable for untreated controls. See figure 1.

Figure 1: Changes observed after a 5-day transdermal CO treatment with DOXYVA. H1-H5: pre-treatment, 10, 30, 60, 90, and 120 minutes after; blue trace: control, orange trace: treatment. (A) Changes in O saturation (B) Decrease in heart rate due to treatment (C) Masimo measurements of PI.

In light of these results, Prof. Puruhitos team performed extra measurements of transcutaneous carbon dioxide (TcPCO), O saturation, and PI in the 15 patients treated with DOXYVA for transdermal CO delivery. This data show that the oxygen saturation reached almost 100% in some patients, whereas the TcPCO remained relatively stable throughout the treatment time (120 minutes). For more detailed information, see figure 2.

Figure 2: Transcutaneous CO pressure (TcPCO), O saturation, and PI assessment in the 15 patients subjected to transdermal CO. (A) SENTEC TcPCO measurements for all patients at various time points after DOXYVA application (pre-treatment, 5, 60, 90, and 120 minutes after) (B) O saturation (C) PI.

Finally, Prof. Puruhitos team demonstrated the positive effects of transdermal CO delivery via DOXYVA on the healing of DFUs (fig. 3), proving the clinical potential of this intervention to improve the quality of life of people suffering from this common complication of diabetes.

In conclusion, the use of a DOXYVA device for transdermal CO delivery improves the outcomes of DFUs by enhancing dermal microcirculation and increasing perfusion rates and tissue oxygenation, therefore assisting in the healing process of the ulcers typical of diabetes neuropathy.

About DOXYVADOXYVA (deoxyhemoglobin vasodilator) is a novel, clinically validated blood flow and nerve stimulant for people suffering from neuropathy. In various clinical trials, DOXYVA has validated leading independent research results and demonstrated above-average results in improving a host of physiological functions.

Subjects suffering from high blood sugar have reported neuropathy pain relief minutes after DOXYVA was administered and long-term blood sugar level improvements after just a few weeks.

Rapid and gentle skin delivery (over-the-skin) with the DOXYVA lightweight, handheld device has prompted improvements in blood microcirculation or PI by 33%* on average in all participants. Lasting results have been measured at 5-60 minutes and up to 4 hours after a single 5-minute DOXYVA delivery on the skin surface without reduction in PI levels.

About Prof. PuruhitoIto Puruhito, MD is professor in the Department of Thoracic and Cardiovascular Surgery at Dr. Soetomo General Hospital as well as a senior lecturer in the Faculty of Medicine at Universitas Airlangga (Indonesia). From 2001 to 2016, he was the rector of the aforementioned university. Prof. Puruhito finished his medicine studies at Universitas Airlangga in 1967, and in 1972 he received a doctorate degree, graduating cum laude from Frederich-Alexander University (Erlangen-Nrnberg, Germany). In his native country, he developed the Department of Thoracic-Cardiovascular Surgery at his former university, Universitas Airlangga, Surabaya. In 1978, he co-founded the Indonesian Association of Thoracic, Cardiac and Vascular Surgery. Prof. Puruhito has authored numerous indexed research articles in Scopus, ISI-Thompson or PUBMED, and scientific presentations and written several books in Indonesian, English, and German. He acted as reviewer for peer-reviewed journals such as Medical Tribune, Annals of Thoracic and Cardiovascular Surgery, Asian Annals of Surgery, Medicinus, and many more Indonesian medical-surgical journals. Currently, apart from lecturing, Prof. Puruhito actively researches stem cells, cardiovascular medicine, and surgery at the Institute of Tropical Disease as well as some work in microcirculation. Further, he acts as coordinator of research affairs at the Department of TCV-Surgery at Dr. Soetomo General Hospital Surabaya. Since 2014, he has been the chairman of the Council of Research in the Ministry of Research Technology and Higher Education of the Republic of Indonesia.

About Circularity Healthcare, LLCCircularity Healthcare, LLC, located in Los Angeles, CA, is a private biotech and medtech products and services company that designs, makes, markets, sells, distributes, and licenses its patented and patent-pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, DOXYVA. One of the main mechanisms underlying DOXYVAs science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products in large and small clinics and hospitals to help enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital, and patient financing at industry-leading terms and speed.

For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com; doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info(at)doxyva(dot)com, info(at)circularityhealthcare(dot)com, or by phone (toll free) at 1-855-5DOXYVA or 1-626-240-0956.

References:

1.Rogers, L. C., Muller-Delp, J. M. & Mudde, T. A. Transdermal delivery of carbon dioxide boosts microcirculation in subjects with and without diabetes, Information summary for healthcare professionals. Circularity Healthcare, LLC2.Puruhito, I. et al. DOXYVA Medical Device, a Potentially Cost-Efficient and Safe Adjuvant Therapy for Diabetic Ulcers: A Pilot Study. J Vasc Surg (2019).3.Puruhito, I., Soebroto, H., Sembiring, Y. & Nur Rahmi, C. Observation of O2 Saturation after transdermal CO2 delivery using Doxyva apparatus.4.Jayarasti, K. & Puruhito, I. Preliminary study of measurement of TcPCO2 using SENTEC device.5.Nur Rahmi, C. Pengaruh Pemberian Transdermal CO2 terhadap Output Perawatan Luka Kaki Diabetik Wagner I dan II. (2018).6.D`OXYVA Relief from neuropathic pain. D`OXYVA https://doxyva.com/complete-fast-advanced-painless-relief-from-neuropathic-pain/.

Forward-Looking InformationThis press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to managements expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Originally posted here:
D'OXYVA improves dermal microcirculation and promotes wound healing in the diabetic foot - PR Web

Cardiac Stem Cells Comments Off on D’OXYVA improves dermal microcirculation and promotes wound healing in the diabetic foot – PR Web | January 10th, 2020

Cara Gormallys pregnancy was shadowed by grief. As a queer woman wanting to have a baby, the biology professor had figured finding a sperm donor would be the only obstacle she and her partner faced. But thanks to Gormallys organizational skills and love of making lists, the couple landed on a donor with relative ease.

Then, Gormally struggled to conceive. Each month brought fresh disappointment and loss.

So much of the process depended on random, heart-breaking chance, she says. The emotional and financial roller coaster was exhausting.

But it wasnt the hardest part. The couple had accepted that, as much as they wanted a baby, their child wouldnt be biologically related to Gormallys spouse.

I grieved that our child wouldnt be genetically related to both of us, Gormally says. I longed for the biologically impossible.

But now, a new set of technologies have the potential to change whats possible allowing same-sex partners to have kids who share their genetic material, just like straight couples.

In mammals, pretty much every cell in the body carries two sets of genetic material. One set comes from mom and the other from dad. Eggs and sperm are the only exceptions; they have just one set. Then, when a sperm fertilizes an egg, those two sets combine, restoring the usual number to two sets per cell.

Gormally and other same-sex partners are currently barred from their dreams by a phenomenon called genomic imprinting. It uses a distinct tag from each parent to mark the DNA that mammals pass on to their offspring. The process ensures that, for a small percentage of genes, we only express the copy of genetic material provided by our mother or our father. When this imprinting process goes awry, kids can end up with inactive gene regions that cause miscarriages, developmental defects and cancer.

(Credit: Jay Smith/Discover)

During this genomic imprinting, moms distinct collection of tags typically turns off certain genes, so that just dads copy is expressed. And dad imparts his own marks that leave only the maternal copy on. (Most imprints silence gene expression, but some activate it.) Thats a problem for same-sex couples who want to have a baby. If both sets of an offsprings genes come from maternal DNA, for example, then both copies of imprinted genes will be off. So, the embryo cant make any of the genes products.

We dont get the full set of [gene] products that we need to undergo proper development unless we have both a maternal and paternal contribution to a fertilized egg, says Marisa Bartolomei, a geneticist at the University of Pennsylvania in Philadelphia, who discovered one of the first imprinted genes in mice.

Scientists discovered genomic imprinting in mammals about 30 years ago. During experiments in the mid-1980s, researchers removed either the maternal or paternal genetic contributions from newly fertilized mouse eggs. Then, they transferred in a second set of genes from another mouse to create embryos with either two sets of female genetic material or two sets of male genetic material. A surrogate mouse was able to gestate the embryos, but none survived. The finding showed normal development requires genetic material from both a father and the mother. More than that, the outcomes revealed that maternal and paternal genetic material differ from each other in meaningful ways.

Later experiments revealed mice developed differently depending on whether they happened to receive both copies of certain regions of DNA from one parent (rather than one copy from each parent).

Mice with hairpin-shaped tails were telling examples. When researchers deleted the gene region responsible for a hairpin tail from a mothers genome, mice embryos grew large and died partway through gestation. In contrast, deleting the same region from the paternal genome had no effect on the rodents growth or development.

In the three decades since, researchers have found more imprinted genes (they suspect there are between 100 and 200 such genes) and the molecular tags that silence them. Scientists have also taken strides connecting imprinting defects to developmental disorders in humans. But all along, researchers have known that imprinting prevents same-sex parents from having children.

In October 2018, researchers overcame this impossibility in mice. By deleting imprinted regions, Wei Li and a team at the Chinese Academy of Sciences in Beijing produced healthy mice from two moms. The researchers also created mouse pups from two dads for the first time. However, the offspring died just a few days after birth.

Despite the loss, Li is optimistic. This research shows us what is possible, he says.

To overcome the imprinting barrier, Li and his fellow researchers turned to CRISPR, a gene-editing technique thats made altering genomes easier than ever. They used the tool to delete gene regions from embryonic stem cells from mice mothers. The researchers then injected these modified stem cells into the egg of a female mouse and then used a third surrogate female mouse to carry the fetus to term.

The team had already seen some success two years earlier when they created mouse pups with two genetic mothers by deleting two imprinted regions. Although these bimaternal mice also grew to adulthood and produced pups of their own, they developed growth defects. On average, the bimaternal mice were 20 percent lighter than their hetero-parental counterparts. In their latest study, Li and his team also deleted a third region from the mothers genes, which restored the animals growth to normal.

But the scientists had to clear a few more hurdles to generate mice with two genetic fathers. They found, through a process of trial and error, that they needed to remove twice as many imprinted regions in the bipaternal mice as the bimaternal mice. In total, the team deleted seven imprinted regions to successfully create mice from two dads.

Still, the numbers were not in their favor. Only two and a half percent of embryos made it to term and less than half of one percent lived for two days. None made it to adulthood.

The produced bipaternal mice are not viable, which implies more obstacles are needed to cross to support their postnatal survival, if possible, Li says. The lower birth rate, on the other hand, implies the existence of an unknown barrier hindering the development of bipaternal embryos.

In contrast, the bimaternal mice fared much better. These mice grew to adulthood and were healthy enough to have pups of their own by mating with typical male mice. They also behaved the same as the control mice. As far as the researchers could tell, the bimaternal mice appear as healthy and normal as any other laboratory mice.

It does not mean that they are normal in every aspect, Li cautions. One cannot investigate all the aspects under restricted experimental conditions with a limited number of animals.

Despite the researchers success, Li says the technique is not ready for use in humans. It is never too much to emphasize the risks and the importance of safety before any human experiment, he says, particularly in regard to the bipaternal offspring, which currently are severely abnormal and cannot survive to adulthood.

The bimaternal offspring hold more promise. The team is now working to translate their findings to monkeys. And that work could bring the impossible one step closer to feasible for humans.

Lis research is encouraging but its a long way from helping Gormally and her spouse. However, its also not the only shot for same-sex couples. Another new technology called in vitro gametogenesis, or IVG, may be an alternative potential path for same-sex couples to have their own kids.

Scientists use the technique to make eggs and sperm from other cells in the body. To do so, biologists first reprogram adult skin cells to become stem cells. Then, they stimulate the skin-derived stem cells to develop into eggs or sperm.

Researchers from Japan have now perfected the technique in mice. And in groundbreaking work, Katsuhiko Hayashi and Mitinori Saitou and their team generated functional eggs from mice tail cells.

The researchers then fertilized the eggs with sperm from male mice and implanted the embryos into surrogate mothers. The offspring grew up healthy and fertile. In principle, this approach could allow a womans skin cells to be engineered into sperm and used to fertilize her partners egg.

IVG could transform same-sex couples ability to have their own children. If it had been possible at the time, we definitely wouldve have tried to do it, says Gormally, who is now a proud parent to a toddler thanks to her and her spouses sperm donor. [Its] a total game-changer.

This story is part of "The Future of Fertility" a new series on Discover exploring the frontiers of reproduction.

Read more:

Can Humans Have Babies in Space?

George Church Wants to Make Genetic Matchmaking a Reality

Human Gene Editing is Controversial. Shoukhrat Mitalipov Isn't Deterred

Visit link:
The Slow March Toward the First Same-Sex Couple to Have a Baby - Discover Magazine

Skin Stem Cells Comments Off on The Slow March Toward the First Same-Sex Couple to Have a Baby – Discover Magazine | January 8th, 2020

Last year left us with this piece of bombshell news: He Jiankui, the mastermind behind the CRISPR babies scandal, has been sentenced to three years in prison for violating Chinese laws on scientific research and medical management. Two of his colleagues also face prison for genetically engineering human embryos that eventually became the worlds first CRISPRd babies.

The story isnt over: at least one other scientist is eagerly following Hes footsteps in creating gene-edited humans, although he stresses that he wont implant any engineered embryos until receiving regulatory approval.

Biotech stories are rarely this dramatic. But as gene editing tools and assisted reproductive technologies increase in safety and precision, were bound to see ever more mind-bending headlines. Add in a dose of deep learning for drug discovery and synthetic biology, and its fair to say were getting closer to reshaping biology from the ground upboth ourselves and other living creatures around us.

Here are two stories in biotech were keeping our eyes on. Although successes likely wont come to fruition this year (sorry), these futuristic projects may be closer to reality than you think.

The idea of human-animal chimeras immediately triggers ethical aversion, but the dream of engineering replacement human organs in other animals is gaining momentum.

There are two main ways to do this. The slightly less ethically-fraught idea is to grow a fleet of pigs with heavily CRISPRd organs to make them more human-like. It sounds crazy, but scientists have already successfully transplanted pig hearts into baboonsa stand-in for people with heart failurewith some recipients living up to 180 days before they were euthanized. Despite having foreign hearts, the baboons were healthy and acted like their normal buoyant selves post-op.

But for cross-species transplantation, or xenotransplants to work in humans, we need to deal with PERVsa group of nasty pig genes scattered across the porcine genome, remnants of ancient viral infections that can tag along and potentially infect unsuspecting human recipients.

Theres plenty of progress here too: back in 2017 scientists at eGenesis, a startup spun off from Dr. George Churchs lab, used CRISPR to make PERV-free pig cells that eventually became PERV-free piglets after cloning. Then last month, eGenesis reported the birth of Pig3.0, the worlds most CRISPRd animal to further increase organ compatibility. These PERV-free genetic wonders had three pig genes that stimulate immunorejection removed, and nine brand new human genes to make themin theorymore compatible with human physiology. When raised to adulthood, pig3.0 could reproduce and pass on their genetic edits.

Although only a first clinical propotype that needs further validation and refinement, eGenesis is hopeful. According to one (perhaps overzealous) estimate, the first pig-to-human xenotranplant clinical trial could come in just two years.

The more ethically-challenged idea is to grow human organs directly inside other animalsin other words, engineer human-animal hybrid embryos and bring them to term. This approach marries two ethically uncomfortable technologies, germline editing and hybrids, into one solution that has many wondering if these engineered animals may somehow receive a dose of humanness by accident during development. What if, for example, human donor cells end up migrating to the hybrid animals brain?

Nevertheless, this year scientists at the University of Tokyo are planning to grow human tissue in rodent and pig embryos and transplant those hybrids into surrogates for further development. For now, bringing the embryos to term is completely out of the question. But the line between humans and other animals will only be further blurred in 2020, and scientists have begun debating a new label, substantially human, for living organisms that are mainly human in characteristicsbut not completely so.

With over 800 gene therapy trials in the running and several in mature stages, well likely see a leap in new gene medicine approvals and growth in CAR-T spheres. For now, although transformative, the three approved gene therapies have had lackluster market results, spurring some to ponder whether companies may cut down on investment.

The research community, however, is going strong, with a curious bifurcating trend emerging. Let me explain.

Genetic medicine, a grab-bag term for treatments that directly change genes or their expression, is usually an off-the-shelf solution. Cell therapies, such as the blood cancer breakthrough CAR-T, are extremely personalized in that a patients own immune cells are genetically enhanced. But the true power of genetic medicine lies in its potential for hyper-personalization, especially when it comes to rare genetic disorders. In contrast, CAR-Ts broader success may eventually rely on its ability to become one-size-fits-all.

One example of hyper-tailored gene medicine success is the harrowing story of Mila, a six-year-old with Batten disease, a neurodegenerative genetic disorder that is always fatal and was previously untreatable. Thanks to remarkable efforts from multiple teams, however, in just over a year scientists developed a new experimental therapy tailored to her unique genetic mutation. Since receiving the drug, Milas condition improved significantly.

Milas case is a proof-of-concept of the power of N=1 genetic medicine. Its unclear whether other children also carry her particular mutationBatten has more than a dozen different variants, each stemming from different genetic miscodingor if anyone else would ever benefit from the treatment.

For now, monumental costs and other necessary resources make it impossible to pull off similar feats for a broader population. This is a shame, because inherited diseases rarely have a single genetic cause. But costs for genome mapping and DNA synthesis are rapidly declining. Were starting to better understand how mutations lead to varied disorders. And with multiple gene medicines, such as antisense oligonucleotides (ASOs) finally making a comeback after 40 years, its not hard to envision a new era of hyper-personalized genetic treatments, especially for rare diseases.

In contrast, the path forward for CAR-T is to strip its personalization. Both FDA-approved CAR-T therapies require doctors to collect a patients own immune T cells, preserved and shipped to a manufacturer, genetically engineered to boost their cancer-hunting abilities, and infused back into patients. Each cycle is a race against the cancer clock, requiring about three to four weeks to manufacture. Shipping and labor costs further drive up the treatments price tag to hundreds of thousands of dollars per treatment.

These considerable problems have pushed scientists to actively research off-the-shelf CAR-T therapies, which can be made from healthy donor cells in giant batches and cryopreserved. The main stumbling block is immunorejection: engineered cells from donors can cause life-threatening immune problems, or be completely eliminated by the cancer patients immune system and lose efficacy.

The good news? Promising results are coming soon. One idea is to use T cells from umbilical cord blood, which are less likely to generate an immune response. Another is to engineer T cells from induced pluripotent stem cells (iPSC)mature cells returned back to a young, stem-like state. A patients skin cells, for example, could be made into iPSCs that constantly renew themselves, and only pushed to develop into cancer-fighting T cells when needed.

Yet another idea is to use gene editing to delete proteins on T cells that can trigger an immune responsethe first clinical trials with this approach are already underway. With at least nine different off-the-shelf CAR-T in early human trials, well likely see movement in industrialized CAR-T this year.

Theres lots of other stories in biotech we here at Singularity Hub are watching. For example, the use of AI in drug discovery, after years of hype, may finally meet its reckoning. That is, can the technology actually speed up the arduous process of finding new drug targets or the design of new drugs?

Another potentially game-changing story is that of Biogens Alzheimers drug candidate, which reported contradicting results last year but was still submitted to the FDA. If approved, itll be the first drug to slow cognitive decline in a decade. And of course, theres always the potential for another mind-breaking technological leap (or stumble?) thats hard to predict.

In other words: we cant wait to bring you new stories from biotechs cutting edge in 2020.

Image Credit: Image by Konstantin Kolosov from Pixabay

More here:
The Top Biotech Trends We'll Be Watching in 2020 - Singularity Hub

Skin Stem Cells Comments Off on The Top Biotech Trends We’ll Be Watching in 2020 – Singularity Hub | January 8th, 2020

PLC () dipped 3% to 286.52p in mid-afternoon after announcing the acquisition of multi-let office space in Staines, Surrey, as well as the sale of a London building to a private developer.

TWENTY was bought for 19mln, is currently let to four tenants and has a vacancy of 23%, while Quayside Lodge in Fulham, London, was sold for the same amount.

TWENTY Kingston Road offers strong reversionary potential with a yield of 7% once fully let and the acquisition is in line with our opportunistic approach, chief executive Fredrik Widlund said in a release.

s () lost 2% to 227.01p after posting like-for-like sales including fuel fell 1.1% in the 15 weeks to 4 January, while total retail sales slipped 0.9%.

The LFL sales slip was slightly worse than analyst expectations which had predicted that sales in the period would be mostly flat.

The FTSE 100 grocer is another major name in the sector suffering sales declines over the so-called golden Christmas quarter.

PLC () gained 6% to 86.63p in early afternoon trades on the back of an acquisition from Cemex SAB de CV ADR ().

The AIM-listed construction materials company will snap up the UK arm and some operation of the Mexican company for 178mln in cash, debt-free.

It will add 170mln tonnes of mineral reserves and resources while adding to the development of Breedons national asphalt strategy and increasing footprint in areas where it is underrepresented.

() rose 7% to 0.41p after updating investors on the Bonya tungsten and copper deposit in Australia resource potential.

Thor is drilling to establish Bonya as a source of ore to extend the life of its nearby Molyhil project.

Latest holes to be drilled showed best results of a 23m intersection at a grade of 0.58% WO3 (tungsten) from the surface at White Violet and a 9m copper band at Samarkand.

Pharos Energy PLC (LON:PHAR) slipped 5% to 55p at lunchtime after informing investors that the 2020 dividend will be halved compared to the 2019 payment.

The oiler will issue 2.75p per share, a yield of 5% on yesterday's close of 58p, to focus on capital investment in the expanded portfolio.

Production in Egypt came as a disappointment as well, with 6mln barrels of oil per day (boe/d) as opposed to the 6.5mln boe/d guidance.

() lost 4% to 156.5p as the footwear retailer posted lower profits but managed to keep the final divi at 8p per share.

The AIM-listed firm attributed the decline to government imposed increases in its operating costs.

For the year ended 5 October, the company reported an underlying pre-tax profit of 9.8mln, down from 11.4mln in the prior year, while revenues edged up 0.9% to 1.62bn.

MPAC Group PLC () shares were trading 16% higher at 240p in late morning after upgrading full-year profit expectations for the second time in four months.

The company, which provides high speed packaging and automation services, attributed the continuing momentum to a strong Q4 order intake and accelerated project execution.

I am confident that we will be able to report an excellent financial performance for 2019 and improved outlook for 2020 which gives us confidence for the future progress of the business, chief executive Tony Steels said in a release.

()(NASDAQ:MTP) hiked 24% to 3.4 on the back of positive results from additional studies on its MTD201 cancer drug.

The analysis revealed the candidate can be delivered via an injection under the skin rather than into the muscle.

It is a key advantage paving the way for approval, while a pivotal study is planned for later in the first half with preparations already underway.

PLC () topped the losers list with a 21% stumble to 65.35p as the mineral resource estimate for its Asacha Gold Mine was reduced after further analysis.

As of 20 December, the asset is estimated to hold 312,558 ounces of gold, as opposed to 553,052 ounces a year before.

The AIM-listed miner is now undertaking a new drilling campaign to upgrade the resources, while formal guidance for the current year will be published shortly.

Travelex owner () was not doing much better with a 16% fall to 130p after updating on the Sodinokibi Windows ransomware attack.

The FTSE 250-listed firm was asked to pay US$6m (4.6m) to restore the customer data they claimed to have swiped from Travelexs systems, or else they would sell it on the dark web.

Finablr said there was no evidence that personal customer data has been encrypted and no evidence that any data has been exfiltrated, adding that Travelex has successfully contained the spread of the ransomware.

() lost 14% to 2.5p after announcing the process for listing on the Hong Kong Stock Exchange is taking longer than expected.

The AIM-listed engineering and technology solutions provider to the bioenergy sector said admission to trades will occur in the first half of 2020.

Management added trading in the second half of 2019 remained strong and is optimistic for the current period.

Asimilar Group PLC (LON:ASLR) jumped 25% higher to 40.66p in early morning trade on Wednesdayafter launching a placing at a premium to Tuesday's closing share price, hot on the heels of last months change of name from YOLO Leisure.

The AIM-listed big data and Internet of Things firm raised 6.8mln by placing 17mln new shares at a price of 40p each withexisting and new investors, a 15% premium to Tuesdays closing price of 33.8p.

Chairman John Taylor said in a release the proceeds will be used to pursue potentially bold and transformative investment options.

() was also onthe gainers list with a 5% push upwards to 247.9p after announcing full-year profit before tax will be comfortably ahead of market expectations.

The financial services provider and retailer mentioned strong trading during the Christmas period, when the jewellery segment recorded double-digit revenue growth.

The company noted that a high gold price boosted profits in the precious metals segment while its pawnbroking and foreign currency divisions continued to produce good results.

() also nudged higher, up 4% to 18.25p as it set up a joint venture with Korean firm Daewoong Pharmaceutical Co.

The firms will develop new cell and gene therapies using Avactas Affimer proteins which will specifically target the development of a new class of mesenchymal stem cells (MSCs), for the treatment of autoimmune and inflammatory diseases.

The AIM-listed company said its research and development costs for these targets will be fully covered by the joint venture which is funded by Daewoong.

() has confirmed that it has received a premium-priced takeover offer from (), and, it is now in advanced talks with the FTSE 100-listed miner. The offer is pitched at 5.5p per share, which is a 34.1% premium to yesterdays closing price of 4.1p. In a statement released after the market close on Tuesday, Siriuss management team said it would be prepared to recommend an offer at that price.

() (NASDAQ:MTP) has hailed the positive results from a study assessing the potential to deliver one of its drugs via an injection under the skin rather than into the muscle. MTD201, which is being developed to treat carcinoid cancer and the growth hormone condition acromegaly, was able to maintain the correct levels of plasma octreotide over six to eight weeks using this subcutaneous method, researchers found.

() has signed an exclusive agreement worth up to US$63mln for its iron deficiency treatment Feraccru to be sold in China. The deal with ASK Pharm (Beijing Aosaikang Pharmaceutical), covers China, Hong Kong, Macau and Taiwan and will involve an upfront payment of US$11.4mln and up to US$51.4mln in milestone and royalties. ASK Pharm will also pay for the marketing authorisation process and commercialising of Feraccru, which is branded as Accrufer in the US.

() has set up a joint venture to develop new cell and gene therapies using its Affimer proteins. The new JV with Daewoong Pharmaceutical Co will specifically target the development of a new class of mesenchymal stem cells (MSCs), multipotent cells where functions can include being agents for the treatment of autoimmune and inflammatory diseases.

() has signed a one-year exclusive evaluation agreement with Corteva Agriscience. The American giant, valued at US$21bn, wants to assess the potential of the UK biopesticides specialists encapsulation technology, focusing on formulations for seed treatments.

() said it has now completed the fundraising it announced on 30 September 2019, which in total raised approximately 412,000, with the final stage raising 150,360 via an issue of 2,148,000 new ordinary shares at a price of 7p each to Zark Capital Limited. Following the issue, Zark will hold 6,000,000 ordinary shares, representing 9.7% of ADMs issued share capital.

() is to trial its graphene-enhanced asphalt Gipave at Romes Fiumicino airport. Gipave will be tested for six months on the airports Alpha taxiway, which handles intercontinental aircraft such as Boeing 777s and Airbus A380s.

() said it has won two large contracts for delivery of Knowledge Capture, part of its information management suite of products, with a minimum combined contract value of 0.9mln over their minimum term. In a statement, the leading global big data technology company noted that the latest contract wins add to a growing list of multi-national clients for both the group's RAPid supply chain analytics and information management solutions, adding 200,000 to the company's annual recurring revenue.

() announced that it has delivered network services to more than 100 hospital and specialist care sites as part of a government contract with the NHS. AdEPT was contracted in 2018 to improve network and bandwidth capacity, to allow for financial savings and better access to clinical systems, after the previous connection managed by () was deemed obsolete.

Group PLC () has seen strong inflows of new money in the first three months of its current year. The sustainable investment specialist said funds under management rose 7% to 16.1bn in the quarter to December with 771mln of new funds and a 289mln gain from market movements.

() has sold its UK B2C business for 200,000 as part of its restructuring plans. In an announcement after the close on Tuesday, the online gaming platform operator said the B2C business was sold by administrators to Grace Media Limited, and the firm had now entered a B2B partnership with Grace Media to facilitate continued delivery of its B2C services to its white label partners, through which it will receive monthly royalties

() on Wednesday confirmed the receipt of US$6.7mln in oil payments from the Kurdistan Regional Government (KRG). In a statement, the Iraq-based crude producer reported that the partners in the Taq oil field were paid US$6.7mln gross for oil sales in August 2019, and, its 44% net share amounted to US$3.6mln.

() has released a statement informing investors that it has received notice of a potential claim against the company from a former energy advisor, Askell Limited. In a brief statement, the small cap oiler said: AAOG believes the Askell claim is without merit and the company intends to defend the claim vigorously.

() has announced the appointment of Oscar Marin Garcia as a non-executive director of the company with immediate effect. The group noted that Garcia has over 20 years' experience, specialising in retail business in the Extremadura region of Spain and managing family office investments, and is co-founder and CEO of Lider Aliment, SA, a 200mln sales family owned company. W resources pointed out that Garcia has a beneficial interest in 114,655,600 ordinary shares, representing approximately 1.8% of the companys share capital.

() said that, further to its announcement on 23 December 2019, the sale of its Malaysian business to AAA Management Science Academy PLT for a total cash consideration of MYR 400,000 (approximately 75,000), payable over a 13 month period, has duly completed. Sam Malafeh, CEO of Malvern, commented: "We are delighted to have completed this transaction, as we can now bring greater focus to growing our UK and Singapore operations."

() said it, has collaborated with BMW Group to integrate its FOVIO driver monitoring technology into the BMW i Interaction EASE. It noted that this integration will be featured at the CES 2020 technology show in Las Vegas at the BMW booth Tech East Outside Area. The firm noted that BMW i Interaction EASE leverages Seeing Machines' technology as a component of their innovative HMI (Human-Machine Interface) concept, visualized through a windshield projected Head-up Display (HUD). It added that Seeing Machines' SVP of Fleet and Human Factors, Dr Mike Lenn, will also be conducting daily presentations on BMW's CES booth from Wednesday through Friday.

() announced that it has terminated its broker services agreement with GMP . Shore Capital Stockbrokers Limited is now the company's sole broker and Strand Hanson Limited continues to act as the company's Nominated & Financial Adviser, the group said.

Bluebird Merchant Ventures () announced that its Annual General Meeting, held on 28 December 2019 in Jersey, all resolutions were duly passed.

Read the original here:
CLS Holdings dips over acquisition, sale - Proactive Investors UK

Skin Stem Cells Comments Off on CLS Holdings dips over acquisition, sale – Proactive Investors UK | January 8th, 2020

Its time to dip into the animal file and I thought Id feature some local animals. Researchers at University of Guelph in Canada have discovered the type of stem cell thats behind the gecko's ability to regrow its tail, a finding that has implications for spinal cord treatment in humans.

In a study published in the Journal of Comparative Neurology, they reported that the spinal cord in a geckos tail contains both stem cells and proteins known to support stem cell growth. Geckos can regrow a new tail within 30 days, faster than any other lizard. As we all know, they detach their tails when grabbed by a predator. The severed tail continues to wiggle, distracting the predator long enough for the gecko to escape.

In the lab, the researchers pinched the gecko's tail, causing it to drop. After detachment, the body wound began to repair itself, eventually leading to new tissue formation and a new spinal cord. The scientists then investigated what happens at the cellular level before and after detachment.

They discovered that the spinal cord houses a special type of stem cell known as the radial glia which is normally inert. But when the tail detaches, the cells make different proteins and begin to divide and make more new cells. Ultimately, they make a brand-new spinal cord. Once the injury is healed and the spinal cord restored, the cells return to a resting state."

Humans respond to spinal cord injury by making scar tissue. The scar tissue seals the wound quickly, but it prevents regeneration, which is why humans have a limited ability to repair our spinal cords. Were missing the key cell types required. The researchers hope to eventually apply their new knowledge to help humans with spinal cord injuries.

A well-known danger here in our islands is divers who get the bends, a painful and potentially life-threatening decompression sickness that strikes scuba divers who surface too quickly. Did you ever wonder if whales and other marine mammals can get the bends? A new study conducted by researchers at the Woods Hole Oceanographic Institution and published in the journal Proceedings of the Royal Society examines how marine mammals generally avoid getting the bends and how they can succumb under stressful conditions.

When humans make deep dives, their lungs compress and that collapses their alveoli, the tiny lung sacs where gas exchange occurs. Nitrogen bubbles build up in their bloodstream and tissues. If they ascend slowly, the nitrogen can return to the lungs and be exhaled. But if they ascend too fast, the nitrogen bubbles don't have time to diffuse back into the lungs. Under less pressure at shallower depths, the nitrogen bubbles expand in the bloodstream and tissue, causing pain and damage.

But whales, dolphins and porpoises have unusual lung architecture which creates two different pulmonary regions which cause their lungs to partially compress. Scientists assumed that this partial compression was the main adaptation sea mammals have to avoid taking up excessive nitrogen at depth and getting the bends.

The researchers took scans of a deceased dolphin, seal, and a domestic pig pressurized in a hyperbaric chamber and discovered that blood flows mainly through the collapsed region of the lungs. That allows some oxygen and carbon dioxide to be absorbed by the animal's bloodstream, while minimizing or preventing the exchange of nitrogen. The pig didnt show that structural adaptation.

Scientists once thought that diving marine mammals were immune from decompression sickness, but a 2002 stranding event linked to navy sonar exercises revealed that 14 whales that died after beaching off the Canary Islands had gas bubbles in their tissues, a sign of the bends. The researchers think that excessive stress may cause the system to fail and increase blood flow to the air-filled regions.

This study may help explain why so many marine mammals are dying and probably also implies that we humans are to blame. I hope somebody pays attention!

Read more from the original source:
Gecko tails and whale bends | Featured Columnists - The Guam Daily Post

Spinal Cord Stem Cells Comments Off on Gecko tails and whale bends | Featured Columnists – The Guam Daily Post | January 8th, 2020

PANDAS emerged in the late 1980s in the wake of a resurgence of rheumatic fever in Pennsylvania, Utah and Missouri. Rheumatic fever is an immune response to group A streptococcus, the bacterial strain that causes strep throat and scarlet fever. It arises when those infections are not treated properly, usually in children. In the worst cases, it can lead to heart failure or permanent heart damage. Some people need to take antibiotics for a decade or more.

Up to 30 percent of children with rheumatic fever develop distinctive motor and behavioral traits called Sydenham chorea or, less commonly these days, Saint Vitus dance, after the patron saint of neurological conditions. Children with this condition exhibit jerky, involuntary movements of their hands, feet and face. By some accounts, they also become irritable and prone to emotional outbursts, have trouble concentrating and temporarily lose their ability to read and write. A frequent complaint heard from the mother is that the character of her child is completely changed, wrote Canadian physician William Osler, who first characterized Sydenham chorea in 1894.

During the rheumatic fever outbreak, Swedo sent questionnaires to 37 parents, asking them about their childrens behaviors. She says she hoped to find a brain-based explanation for OCD, which had, until then, largely been credited to harsh parenting techniques. The findings confirmed her suspicions: Children with Sydenham chorea had significantly more obsessive thoughts or behaviors than children with rheumatic fever alone. Based on follow-up interviews, Swedo determined that three children diagnosed with Sydenham chorea met the diagnostic criteria for OCD.

Swedo then inverted her approach. Rather than seeking out children with rheumatic fever, she began studying children with OCD and Tourette syndrome, and swabbing their throats for evidence of a strep infection. She often found it which is not surprising because it is a common infection, and many children also carry the bacteria without getting sick. What was surprising, Swedo says, was what happened when she started treating those children.

She recalls one child who refused to swallow his spit, preferring, instead, to stockpile it. He had three cups under his bed, she says. When she treated him with penicillin, she says, he responded beautifully; his obsessive-compulsive symptoms disappeared. He then had another strep infection, and the OCD-like behavior came roaring back. In another child, she tried plasmapheresis, a technique to separate the childs blood cells from the plasma and strip out the germ-fighting antibodies circulating in his system. She says that led to an 80 percent decrease in the boys OCD traits, according to his parents.

Based on those observations and more over the next decade, Swedo came to believe that an immune response to infection can trigger an improperly diagnosed class of psychiatric conditions. She would go on to investigate and rule out other connections between infection and conditions of brain development, including the spurious association between Lyme infection and autism. In 2006, she proposed a trial to test chelation therapy, which some parents of autistic children pursue based on the bogus belief that mercury and other heavy metals in vaccines cause the condition. Critics called the trial unethical and a waste of funding, and it was ultimately abandoned due to safety concerns.

Theres going to be diagnostic confusion whether a child has a late presentation of autism or if they have PANDAS. Susan Swedo

It was PANDAS that would become Swedos legacy. In 1998, Swedo proposed five criteria to diagnose PANDAS: the presence of OCD or a tic disorder, sudden onset prior to puberty, a waxing and waning pattern of trait severity, an association between strep infections and behavioral traits, and neurological abnormalities such as jerking movements or problems with coordination. Despite the clear, testable criteria she laid out, the definition of PANDAS proved elastic in the hands of practitioners. By 2008, one study had found that only 39 percent of children diagnosed with PANDAS actually fit Swedos original definition. So many children were diagnosed, in fact, that Stanford Universitys multidisciplinary PANDAS clinic the first of its kind when it opened in 2012 sees children from within only a seven-county area and only if they agree to participate in research.

Given the surge of interest, the NIH launched a $3 million multicenter study the largest and most rigorous analysis of the condition. The researchers followed 71 children who met PANDAS diagnostic criteria over two years and compared them with children who had traits of Tourette syndrome or OCD but not PANDAS. Two landmark studies, published in 2008 and 2011, found that in 91 percent of all PANDAS cases, there was no association between the timing of strep infections or presence of strep antibodies and flare-ups of OCD or tics. Even though children with PANDAS were more likely to receive antibiotics than the other children were, the researchers could detect no difference in the number of flare-ups the children experienced.

The NIH makes no mention of these studies on its information pages about PANDAS, which Swedo helped draft. To be fair, the results left just enough room for doubts to creep in. Many strep infections go unnoticed and can trigger immune reactions that standard tests do not detect. The researchers consulted Swedo before the trial, but she says they approached it with an agenda to disprove PANDAS. For example, she says, most of the PANDAS children in the study had Tourette syndrome over a long period of time and showed no signs of abrupt-onset OCD, PANDAS hallmark behavioral trait. However, Kaplan, an investigator on those trials, says all of the participants fit Swedos published definition.

Swedo and her colleagues later proposed a new, broader condition that would better fit the state of the evidence: pediatric acute-onset neuropsychiatric syndrome, or PANS. This umbrella diagnosis is not restricted to children with strep or any other type of infection. It might even be caused, for instance, by environmental factors or metabolic disorders. Nor is it limited to young children: PANS can strike anyone up to the age of 18. The main requirement for PANS is the acute onset of OCD or restricted food intake, though the working guidelines make it clear that mild, non-impairing obsessions or compulsions do not rule out the syndrome.

One 2015 study in mice revealed how strep infections could cause brain inflammation, but no studies have followed a large group of children to try to link infections and PANDAS since the NIH-funded studies. Asked why no one has attempted a new study, Swedo says the field has moved on, adding, You cant fight a felonious report with additional data.

Link:
How a controversial condition called PANDAS is gaining ground on autism - Spectrum

Cardiac Stem Cells Comments Off on How a controversial condition called PANDAS is gaining ground on autism – Spectrum | January 8th, 2020

Funding to Support Ongoing Advancement of siFi2, Lead Candidate from Companys First-of-its-Kind Platform for Precisely Controlling Core Cell Migration Mechanisms

New York, NY, January 7, 2020 MicroCures, a biopharmaceutical company developing novel therapeutics that harness the bodys innate regenerative mechanisms to accelerate tissue repair, today announced that it has been awarded a Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The two-year, $1.5 million award will support ongoing development of the companys lead product candidate, siFi2. siFi2, a small interfering RNA (siRNA) therapeutic that can be applied topically, is designed to enhance recovery after trauma. This Phase 2 grant continues the companys successful Phase 1 SBIR contract which demonstrated significantly improved repair of burn wounds following treatment with siFi2 in animal models.

MicroCures technology is based on foundational scientific research at Albert Einstein College of Medicine regarding the fundamental role that cell movement plays as a driver of the bodys innate capacity to repair tissue, nerves, and organs. The company has shown that complex and dynamic networks of microtubules within cells crucially control cell migration, and that this cell movement can be reliably modulated to achieve a range of therapeutic benefits. Based on these findings, the company has established a first-of-its-kind proprietary platform to create siRNA-based therapeutics capable of precisely controlling the speed and direction of cell movement by selectively silencing microtubule regulatory proteins (MRPs).

The company has developed a broad pipeline of therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. Unlike regenerative medicine approaches that rely upon engineered materials or systemic growth factor/stem cell therapeutics, MicroCures technology directs and enhances the bodys inherent healing processes through local, temporary modulation of cell motility. The companys lead drug candidate, siFi2, is a topical siRNA-based treatment designed to silence the activity of Fidgetin-Like 2 (FL2), a fundamental MRP, within an area of wounded tissue. In doing so, the therapy temporarily triggers accelerated movement of cells essential for repair into an injury area. Importantly, based on its topical administration, siFi2 can be applied early in the treatment process as a supplement to current standard of care.

We are grateful for NIHs continued support of our work through this multi-year Phase 2 SBIR grant. This non-dilutive financial support allows us to continue building a robust portfolio of preclinical data in animal models that demonstrate the therapeutic potential of siFi2 to significantly improve and accelerate healing of burn wounds, said David Sharp, Ph.D., co-founder and chief science officer of MicroCures. This funding will help advance our research as we work towards first-in-human clinical trial in 2020.

The initial Phase 1 SBIR grant from NIH funded preclinical research by MicroCures which demonstrated that treatment with siFi2 accelerated re-epithelization, improved collagen deposit and maturation, and improved quality of healing in a porcine full thickness burn model. Specific findings showed that following eight weeks of treatment, 39% of siFi2-treated wounds were closed as compared to only 11% for control subjects and 0% for placebo. Additionally, siFi2-treated subjects demonstrated a significantly improved rate of healing as measured by epithelial surface measurements as compared to placebo (p = 0.0106) and control (p = 0.0012).

About MicroCures

MicroCures develops biopharmaceuticals that harness innate cellular mechanisms within the body to accelerate and improve recovery after traumatic injury. MicroCures has developed a first-of-its-kind therapeutic platform that precisely controls the rate and direction of cell migration, offering the potential to deliver powerful therapeutic benefits for a variety of large and underserved medical applications.

MicroCures has developed a broad pipeline of novel therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. The companys lead therapeutic candidate, siFi2, targets excisional wound healing, a multi-billion dollar market inadequately served by current treatments. Additional applications for the companys cell migration accelerator technology include dermal burn repair, corneal burn repair, cavernous nerve regeneration, spinal cord regeneration, and cardiac tissue repair. Cell migration decelerator applications include combatting cancer metastases and fibrosis. The company protects its unique platform and proprietary therapeutic programs with a robust intellectual property portfolio including eight issued or allowed patents, as well as eight pending patent applications.

For more information please visit: http://www.microcures.com

Disclaimer: The SBIR Grant (2R44AR070696-02A1) is supported by the NIHs National Institute of Arthritis and Musculoskeletal and Skin Diseases. The content of this press release is solely the responsibility of MicroCures and does not necessarily represent the official views of the NIH.

Read more:
MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair - BioSpace

Cardiac Stem Cells Comments Off on MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair – BioSpace | January 8th, 2020

MENLO PARK, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today announced the discovery of a series of novel mitochondrial peptide analogs with potent in vitro activity as selective inhibitors of C-X-C Chemokine Receptor Type 4 (CXCR4) and with preliminary in vivo efficacy in a mouse model of melanoma, including substantial reduction in tumor growth as compared to control animals. CXCR4 is a key regulatory receptor involved in tumor growth, invasion, angiogenesis, metastasis, and resistance to therapy.

This new discovery offers the potential to develop novel therapeutics for difficult-to-treat cancers, based on peptides encoded in the mitochondrial genome, said Ken Cundy, Ph.D., CohBars Chief Scientific Officer. Inhibition of this key regulatory pathway is potentially applicable to a wide range of cancers, as well as orphan indications where CXCR4 signaling is dysregulated.

Novel peptide analogs of a mitochondrially encoded peptide (MBT5) demonstrated potent and selective inhibition of human CXCR4 receptor in cell-based assays, with IC50 values in the low nanomolar concentration range. In a difficult-to-treat in vivo mouse model of melanoma, the B16F10 syngeneic tumor model, the combination of an analog of MBT5 administered subcutaneously with the chemotherapeutic temozolomide showed enhanced antitumor activity, reducing tumor growth after 11 days by 61% compared to control animals. The reduction in tumor growth produced by the combination exceeded the effect of either temozolomide used as a single agent, which reduced tumor growth by 38% compared to control, or the murine checkpoint inhibitor anti-PD-1 antibody, which had no effect on tumor growth in this model.

CohBar plans to further explore the efficacy of this new family of peptides in additional animal models with the goal of identifying a new clinical development MBT candidate.

These new data further expand our understanding of the broad regulatory influence exerted by mitochondria and the therapeutic potential of analogs of peptides encoded in mitochondrial DNA, said Steve Engle, CohBar CEO. We are just beginning to scratch the surface of this previously untapped field.

CXCR4 is overexpressed in more than 75% of cancers and high levels of the receptor are associated with poor survival prognosis. Inhibition of the CXCR4 receptor has been shown to mobilize immune cells, enhance the effects of chemotherapy and immunotherapy in various cancers, and reduce the development of metastatic tumors by blocking the ability of tumor cells to evade immune surveillance. CXCR4 also regulates the homing and retention of hematopoietic stem cells and malignant cells in the bone marrow.

Further details of these new studies will be available on the CohBar website at http://www.cohbar.com.

About CohBar

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBars founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial-derived peptides. CohBars efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, type 2 diabetes, and cardiovascular and neurodegenerative diseases. The companys lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial that includes an evaluation of biological activity relevant to NASH and obesity.

For additional company information, please visit http://www.cohbar.com.

Forward-Looking Statements

This news release contains forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as believe, may, will, estimate, continue, anticipate, intend, could, should, would, project, plan, expect, goal, seek, future, likely or the negative or plural of these words or similar expressions. Examples of such forward-looking statements including but not limited to statements regarding the ability of mitochondrial peptide analogs to reduce tumor growth in mice; anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs and MBTs. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable than and that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; and our ability to establish and maintain partnerships with corporate and industry partners. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at http://www.sec.gov or http://www.sedar.com.

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

Investor and Media Contact:Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650) 445-4441 Jordyn.tarazi@cohbar.com

Joyce AllaireLifeSci Advisors, LLC jallaire@lifesciadvisors.com

Read more here:
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis - Associated Press

Bone Marrow Stem Cells Comments Off on CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis – Associated Press | January 8th, 2020

CALQUENCE (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia

MISSISSAUGA, ON, Jan. 8, 2020 /CNW/ - AstraZeneca Canada today announced that Health Canada has approved Calquence (acalabrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia (CLL), as monotherapy or in combination with obinutuzumab in the first-line setting, and as monotherapy for relapsed/refractory (r/r) disease.1

CLL is the most common type of leukemia in adults, accounting for 44 per cent of all cases in Canada.2 Morethan 2,200 people in Canada are diagnosed with the disease each year and more than 600 will die from it.3,4 Despite advancements in the treatment of CLL, there is still no cure for the disease and even after successful initial treatment, some patients may relapse, leaving them in need of further innovation.

"CLL is most often diagnosed when patients are more than 60 years old, at a time when they are already dealing with other health conditions related to aging and are trying to maintain the best quality of life," says Antonella Rizza, CEO of Lymphoma Canada. "Today's announcement offers Canadians living with CLL an important new option for this incurable but treatable disease."'

The Canadian approval was granted under Project Orbis, a new international health authority collaboration which provides a framework for simultaneous submission and review of oncology products among international partners.5Under this collaboration, Health Canada, the U.S. FDA, and the Australian Therapeutic Goods Administration (TGA) collectively reviewed the application for Calquence, making it the second treatment approved as part of the program and the first in hematology.

"In the last several years, we've been moving away from traditional chemotherapies to more targeted therapies for CLL." said Dr. Carolyn Owen, Alberta Health Services, Calgary. "Health Canada's approval of acalabrutinib provides a new effective and well tolerated treatment option for CLL patients and improves their treatment options."

The Health Canada approval of Calquence was based on positive interim data from two Phase III clinical trials, ELEVATE-TN and ASCEND.6,7The ELEVATE-TN trial evaluated the safety and efficacy of Calquence in combination with obinutuzumab, a CD20 monoclonal antibody, or Calquence alone versus chlorambucil, a chemotherapy, in combination with obinutuzumab in previously untreated patients with CLL. The ASCEND trial evaluated the efficacy of Calquence in previously treated patients with CLL.Together, the trials showed that Calquence in combination with obinutuzumab or as a monotherapy significantly reduced the relative risk of disease progression or death. Across both trials, the safety and tolerability of Calquence were consistent with its established profile.1

About chronic lymphocytic leukemia (CLL)Chronic lymphocytic leukemia is the most common type of leukemia in adults, which begins in the bone marrow, and progresses slowly.8 In CLL, too many blood stem cells in the bone marrow become abnormal lymphocytes and these abnormal cells have difficulty fighting infections.9 As the number of abnormal cells grows there is less room for healthy white blood cells, red blood cells and platelets.9This could result in anaemia, infection and bleeding.9B-cell receptor signalling through BTK is one of the essential growth pathways for CLL. Many people with CLL do not have any symptoms upon diagnosis, and the disease is often found in blood tests for unrelated health problems.10

AboutCalquenceCalquence(acalabrutinib; previously known as ACP-196) is a selective inhibitor of Bruton's tyrosine kinase (BTK).1Calquencebinds covalently to BTK, thereby inhibiting its activity, and has demonstrated this with minimal interactions with other immune cells in pre-clinical studies.1,6,7In B cells, BTK signaling results in activation of pathways necessary for B cell proliferation, trafficking, chemotaxis and adhesion.1 The recommended dose ofCalquenceis one 100mg capsule taken orally twice daily (approximately 12 hours apart), until disease progression or unacceptable toxicity.1Calquencemay be taken with or without food.1

About AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 675 employees across the country and our headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at http://www.astrazeneca.ca.

References

SOURCE AstraZeneca Canada Inc.

For further information: AstraZeneca Corporate Communications, [emailprotected]; Hibaq Ali, Weber Shandwick Canada, [emailprotected] / tel: 416-642-7915

http://www.astrazeneca.ca

View post:
New Treatment Approved in Canada for Most Common Type of Leukemia - Canada NewsWire

Bone Marrow Stem Cells Comments Off on New Treatment Approved in Canada for Most Common Type of Leukemia – Canada NewsWire | January 8th, 2020

(MENAFN - Fior Markets)

Spearheaded by researchers at Baylor College of Medicine divulges a contemporary mechanism that donates to adult bone conservation and restores and unfurls the possibility of advancing the therapeutic plan of action for enhancing bone healing.

Corresponding author Dr. Dongsu Park professor of molecular and human genetics said that adult bone repairs depend on the setting off of bone stem cells which yet remains deficiently distinguished. Bone stem cells have been discovered both in the bone marrow interior of the bone and also in the periosteum the exterior layer of the tissue that wraps the bone. Former studies have portrayed that these two communities of stem cell albeit they apportion various characteristics also have distinctive functions and particular regulatory processes.

Of the two periosteal steam cells are the minimalistcomprehended. It is known that they constitute a heterogeneous population ofcells that can bestow to bone density, molding and rupture restoration,however, scientists had not been able to discern between varied subtypes of thebone stem cell to scrutinize how their varied purposes are controlled.

In the present study Park and his colleagues advanced aprocedure to recognize varied subpopulations of periosteal stem cells expoundtheir benefaction to bone fracture restoration in animate mouse models andrecognize particular components that control their migration and multiplicationunder psychological circumstances.

The researchers found particular trademarks for periosteal stem cells in mouse models. The trademarks recognized a definite subset of stem cells that donates to long-lasting adult bone resurrection.

MENAFN07012020007010660ID1099519082

See the article here:
Contemporary Bone Alleviates Mechanisms Have Prospective Therapeutic Applications - MENAFN.COM

Bone Marrow Stem Cells Comments Off on Contemporary Bone Alleviates Mechanisms Have Prospective Therapeutic Applications – MENAFN.COM | January 7th, 2020

Fourteen charities based in London have won a 1,000 festive boost thanks to nominations from the public.

The charities were nominated to win a share of 120,000 as part of specialist insurer Ecclesiasticals annual 12 days of giving Christmas campaign.

Anthony Nolan, which helps to save lives by matching individuals willing to donate their blood stem cells or bone marrow to people with blood cancer and blood disorders, and Shakespeare Schools Foundation, which helps thousands of young people from across the UK become better at teamwork, more confident and more ambitious (see notes for full list1), are among the local charities set to benefit from the money, following overwhelming public support in the area.

More than 120,000 people around the UK nominated a cause close to their heart, with over 5,000 charitable causes up and down the country receiving votes. The 120 winning charities were picked at random from those nominated.

The full list of the 120 charity winners is available to view online at http://www.ecclesiastical.com/12days

Thanking supporters in London, Mark Hews, group chief executive at Ecclesiastical, said: Here at Ecclesiastical, our core purpose is to contribute to the greater good of society, so charitable giving is at the heart of our business. We know that 1,000 can make a huge difference to the incredible work that charities do and were looking forward to seeing how this festive financial boost will change lives for the better.

Last year, Ecclesiastical launched its second Impact Report to celebrate some of the many good causes it has helped.

Original post:
London charities scoop share of 120000 festive financial boost - London Post

Bone Marrow Stem Cells Comments Off on London charities scoop share of 120000 festive financial boost – London Post | January 7th, 2020

SUZHOU, Chinaand SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced the initiation of an investigational study of GC027, the first product candidate developed using TruUCAR to treat relapsed or refractory (R/R) T-cell malignancies.

T-cell acute lymphoblastic leukemia or T-ALL is an aggressive form of ALL, which affects white blood cells and the bone marrows ability to generate healthy blood cells. About 15-20% of people with ALL have T-ALL. While T-ALL is treatable by chemotherapy and stem cell transplant, around 75% of patients will relapse within two years[1]. T-cell lymphoblastic lymphoma (T-LBL) is another devastating T-cell malignancies. For patients who develop R/R T-ALL or T-LBL, there are few options for treatment.

Autologus CAR-T therapies rely on patients' own T cells, which have been affected by prior therapies; thus, cell quality as well as efficacy remains questionable. Allogenic CAR-T therapies made of healthy donors' T cells would be characterized as being of consistently good quality with the potential to improve efficacy. Unlike autologous CAR-T cells, allogeneic CAR-T cells can be made as off-the-shelf product which means patients do not have to wait for lengthy production time. Furthermore, the cost of production can be significantly lower. Allogenic CAR-T therapies also provide a vital treatment option for patients with viral infections and/or other conditions prohibiting access to autologous cell therapies.

TruUCARbased GC027 is designed to meet the above unmet needs. Its cells are made of T cells from healthy donors, genetically edited and inserted with chimeric antigen receptor (CAR) ex vivo, which can specifically bind to and eliminate target T malignant cells. Different from industry leaders' off-the-shelf CAR-T design, Gracell's proprietary and patented TruUCAR technology requires no co-administration of anti-CD52, a cytotoxic agent for ablating cancerous cells while inducing long term immune depletion in the patient.Instead, GC027 utilizes CRISPRgenome editing strategy that is expected to avoid graft-versus-host disease (GvHD) as well as graft rejection caused by the patients' immune system.

The prudent preclinical studies provide substantial evidence to trigger GC027 moving into a non-IND(investigational new drug)clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of GC027 therapy in patients suffering from relapsed and refractory T lymphocyte malignancies.

TruUCAR is another technological breakthrough developed by Gracell following the recent announcement of FasTCAR technology and products. It enables producing off-the-shelf CAR-T cells from healthy MHC (major histocompatibility complex) mismatched donors with a large number of doses readily to be dispatched to patients in need.

"Launch of the investigational GC027 study as the first-of-its-kind therapy marks another significant milestone for Gracell," said Dr. William CAO, Founder and CEO of Gracell. "Once the concept is well-proved with solid evidence for safety and efficacy, we will immediately deploy development of a series of TruUCAR products for other medical unmet needs, including B cell malignancies."

About GC027

GC027 is an investigational, off-the-shelf CAR-T cell therapy for T cell malignancies, derived from healthy donors. The use of healthy donor's cells are preferential to a patient's own with potential to improve efficacy, reduce production time, and lower cost of goods.

About T-ALL

T lymphoblastic leukemia (T-ALL) is an aggressive form of T cell malignancies, with a diffuse invasion of bone marrow and peripheral blood. In 2015, ALL affected around 876,000 people globally and resulted in 110,000 deaths worldwide. T-ALL compromises about 15%-20% children and adults[1].Current standard therapies for T-ALL are chemotherapies and stem cell transplantation. A large portion of these patients will experience relapse within two years following treatment by conventional therapies.

About T-LBL

T lymphoblastic lymphoma (T-LBL) is an aggressive form of T cell malignancies, with rare lymphoproliferative neoplasm of mature T cells caused by infection with the retrovirus human T lymphotropic virus. T-LBL compromises about 2% of adult non-Hodgkin's lymphoma (NHL) and 30% of pediatric NHL patients[2]. Five-year overall survival is only 14% in adults.Although first-line treatment using cytotoxic combination chemotherapy can achieve 70% ORR, nearly 90% of patients relapse, often within months of completing chemotherapy.

About Gracell

Gracell Biotechnologies Co., Ltd. ("Gracell") is a clinical-stage biopharma company, committed to developing highly reliable and affordable cell gene therapies for cancer. Gracell is dedicated to resolving the remaining challenges in CAR-T, such as high production costs, lengthy manufacturing process, lack of off-the-shelf products, and inefficacy against solid tumors. Led by a group of world-class scientists, Gracell is advancing FasTCAR, TruUCAR (off-the-shelf CAR), Dual CAR and Enhanced CAR-T cell therapies for leukemia, lymphoma, myeloma, and solid tumors.

CONTACT:

[1]Pediatric hematologic Malignancies: T-cell acute lymphoblastic Leukemia, Hematology 2016

[2]Clinical Review: Adult T-cell Leukemia/lymphoma, Journal ofOncology Practice 2017

SOURCE Gracell

http://www.gracellbio.com

Link:
Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR Therapy for Relapsed or Refractory T-cell Malignancies - PRNewswire

Bone Marrow Stem Cells Comments Off on Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR Therapy for Relapsed or Refractory T-cell Malignancies – PRNewswire | January 7th, 2020

Welcome to Try Before You Buy, a monthly series where we talk about the pricey beauty products and in-office treatments that are getting major buzz and give our honest feedback. This month, our Senior Beauty & Fashion Editor, Pia Velasco, talks about theAugustinus Bader cream that has changed her skin.

As a beauty editor, Ive tried hundreds (and maybe even thousands) of skincare products since starting my career seven years ago. There have been creams that promise to give me skin as soft as babys bum, serums that pledge to erase all signs of dark spots, face masks that swear theyll make my skin so radiant that itll blind my enemiesand guess what, most of them fell through on their promises. As such, Ive become skeptical when a brand tells me that their product is life-changing and that there isnt anything like it on the market. So when I met Professor Augustinus Bader, the director of the Applied Stem Cell Biology and Cell Technology at the University of Leipzig in Germany, earlier this year and he and his team told me about his epigenetic skincare line that changes the skin to the point of altering DNA, I have to admit that I did mentally raise an eyebrow.

However, I had heard about epigenetic skincare before and was fascinated by the science behind it. Essentially, epigenetics refers to the naturally occurring biological modification process of the DNA thats influenced by the environment and lifestyle patterns. For example, if you have a healthy diet and exercise on the regular, your genetic coding will eventually change to be healthier, and youll be able to transfer those healthy genes onto your offspring. Epigenetic skincare is the same conceptif you train your skin cells to be healthy, your skins DNA will change. Needless to say,I was curious to try it, and when a fellow beauty editor friend told me that she stopped using all of her skincare products after trying the Augustinus Bader The Rich Cream, I went from being curious to being eager to try it.

A quick background on my skin. Ive always had acne-prone skin, and because of my medium skin tone, Im also very prone to hyperpigmentation. Most of the skincare products I use target my acne concerns, but I also go ham on texture-refining products in hopes that one day Ill achieve glass-like skin. Im used to looking at ingredients that target specific skincare concerns (salicylic acid for acne, retinol for anti-aging, vitamin C for brightening, etc.), and for the first time, I was using a product that claimed that it would address all my concerns at once. Because of the way epigenetic skincare works, instead of targeting just one skincare concern, the product tells skin cells to be healthy, which in turn helps skin be the best version of itself.I know it sounds too good to be true, and while it may not work for everybody, holy shit it worked wonders for me.

Courtesy of Augustinus Bader

I started testing out the cream the way I approach all my beauty testing, I did a test-drive on half my face. On the left side of my face, I continued to use the products that were already in my arsenal, and on the right side of my face, I used the Augustinus Bader cream and nothing else. After about two weeks I started seeing a shiftmy acne wasnt working up, my skin texture was a lot more smooth, and it just looked overall healthier. I quickly tossed my other products and switched over to using The Rich Creamevery day. After a while, my skin started balancing out and both looked and felt a whole lot better. Now, Im not saying this product is magicbut Im also not saying that its not.

Im currently testing a whole new array of skincare products for the upcoming HelloGiggles Beauty Crush Awards (stay tuned!), and so Ive had to sacrifice the left side of my face to test new products (I switch off between sides). As a result, my skin has started to shift back into its old ways, with a resurgence of blemishes, dark spots, and uneven texture as I test out new formulas. But the right side of my face is still in A+ condition.

Sure, this product is definitely on the pricier side, but its a product that I can say with full confidence that I would actually buy if I wasnt a beauty editor. (Full disclosure: I receive a lot of free products from beauty brands, and Ive only bought about a handful of products with my own money since working in the business.) For me, getting my ideal skin has always been a battle, and Im so happy to have finally found a product that works magic for me, which is why I was excited to learn that the brand recently launched a body cream as well.

Courtesy of Augustinus Bader

Its important to remember that body care requires skincare too, after all, we do have skin on our bodies. The Augustinus Bader body cream fulfills the basic requirement of moisturizing skin, but what makes this anti-aging body product stand out is that it uses its epigenetic technology to target and treat stretch marks and cellulite with continued use. Now, I havent used it long enough to speak to its long-term effects, but I can say that its fast-absorbing formula does make my skin feel baby soft and look way smoother than it did before. Also, Im typically very good about sharing my beauty products with others, but when my boyfriend asked if he could use this cream I may or may not have told him Id put a curse on his ancestors if he dared. Nothing gets in the way of me and my Augustinus Bader products.

Originally posted here:
The viral Augustinus Bader rich cream has completely changed my skin for the better - Yahoo Lifestyle

Skin Stem Cells Comments Off on The viral Augustinus Bader rich cream has completely changed my skin for the better – Yahoo Lifestyle | January 7th, 2020

This is a sponsored story

The start of a new year is the perfect time to prioritize self-care and set health and wellness goals, so make 2020 your happiest yet with a new, enhanced version of you. Use this guide to find the doctors, therapists and practitioners that can help you look and feel your best.

When diet and exercise just wont provide the results youre looking for, visit Skiin Anti-Aging Lounge. They offer the only procedure that builds muscle. EMSCULPT has been proven safe and effective by the most reputable scientific methods. The procedure induces strong muscle contractions with Hifem (high-intensity electromagnetic) technology not achievable through voluntary contractions. This builds muscle and creates a sculpted, toned physique. Other services like CoolSculpting and Exilis also help clients reshape their bodies through nonsurgical, noninvasive methods. Skiin is the first and only CoolSculpting advanced education center in the nation. Another first: Exilis is the first and only device to combine radio frequency and ultrasound to tighten skin through heating and cooling.

Your face is the first place to show signs of aging, but there is a way to take back those years. Dr. John Yousif has received several awards for his research in facial aging. He has been practicing plastic and cosmetic surgery for over 30 years and has even pioneered new techniques like the Gortex Midface Lift and the Hyoid Suspension Neck Lift. At both Sier Medi-Spa and Ascension in Mequon, he offers surgical and nonsurgical procedures to reverse the signs of aging. All of the types of facelifts offered are long-lasting and natural looking, leaving clients feeling like a younger version of themselves.

RELATED Wonderful World of Weddings

Aqua, under the direction of Dr. Christopher Hussussian, is a full-service salon, spa and med spa offering a wide range of services in a luxurious setting on Pewaukee Lake. Whether you are hoping to change the way you look or feel or both Aqua has a solution to enhance your skin and hair for both body and face. New services for the new year include hair restoration for both men and women using PRP (platelet-rich plasma) with biotin and a new weight-loss program using the HCG hormone. They also offer advanced laser hair removal, Clear Lift skin tightening, ThermiVa and CoolSculpting, a popular nonsurgical fat cell reduction with lasting results. A consultation can help you decide what services would work best to achieve a healthier, happier version of yourself.

Serving the Lake Country area, Dr. Tom Stamas is helping people put their best face forward, one smile at a time. He specializes in smile design, a full dental restoration and reconstruction for those suffering from tooth damage or loss, or for those looking to fix crooked, worn or yellowed teeth. During your personalized consultation, Stamas and his team will help you select which treatments will bring your smile to life. Dental treatments like bridges, dental implants, crowns and state-of-the-art diagnostic tools are all available to restore the health, function and appearance of your smile. Youll feel good about the natural-looking results, and your self-esteem will get a boost too.

What if you could use undesired fat from your belly to get rid of the bags under your eyes? Sounds too good to be true, right? Anew Skin and Wellness has a procedure that is done right in the office with long lasting results. The nano-fat transfer removes a small amount of fat with micro liposuction. That fat is harvested for re-injection to the appropriate areas of the face, neck, earlobes, hands and thighs. It can also be used to plump thin lips, smooth cellulite and scars and restore skin elasticity. The nano-fat transfer is safe, effective, economical and helps clients look their best. The in-office procedure provides long-lasting results because the bodys stem cells can turn the aging skin into new, rejuvenated skin. Its the natural way to tighten and smooth skin, allowing you to turn back the clock without a surgical face- or neck-lift.

RELATED Where Should You Brunch this Weekend? We've Got 9 Suggestions

Dr. Arvind Ahuja has provided neurosurgical and endovascular care in southeastern Wisconsin for more than 20 years for brain, spine, artery and peripheral nerve conditions. Whether patients come to Neurosurgery and Endovascular Associates for neck and/or arm pain, back and/or leg pain or headache, the first step is always diagnostic testing to determine the cause of the pain, rather than just treating the symptoms. Often through treatments like medication, steroid injections, physical therapies and if need be surgery, patients achieve improved functioning and long-term relief. Ahujas specialized training in the nervous system is incredibly effective in treating spinal conditions, and his treatments give patients the opportunity to live a happier and morefunctional life.

Excerpt from:
How These Practitioners Can Help with New Year, New You Goals - Milwaukee Magazine

Skin Stem Cells Comments Off on How These Practitioners Can Help with New Year, New You Goals – Milwaukee Magazine | January 7th, 2020

NEW YORK, Jan. 7, 2020 /PRNewswire/ --

Report Includes: - An overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies

Read the full report: https://www.reportlinker.com/p05835679/?utm_source=PRN

- Discussion on role of genomic and epigenomics manipulations in generating safe and effective treatment options - Identification of autologous and allogeneic cells and their usage in creating advanced therapy medical products (ATMPs) - Information on 3D cell culture and discussion on advances in gene editing and gene programming techniques such as CRIPSR/Cas9, TALEN, and ZINC fingers - Insights into commercial and regulatory landscape, and evaluation of challenges and opportunities for developing autologous and allogenic "off the shelf" solutions

Summary Stem cells are unique in their ability to divide and develop into different cell types that form tissues and organs in the body during development and growth.The stem cell's role is to repair impaired or depleted cells, tissues and organs in the body that are damaged by disease, injury, or normal wear and tear.

Stem cells are found in every organ, but are most abundant in bone marrow, where they help to restore the blood and immune system.

Stem cells may be derived from various sources, including - - Adult stem cells (ASCs): Derived from tissue after birth, these include bone marrow, brain, peripheral blood, skeletal muscle, skin, teeth, heat, gut, liver, ovarian epithelium and testis, as well as umbilical cord stem cells and blood. These cells are currently most widely used for cellbased therapies. Hematopoietic stem cells (HSCs), which are derived from bone marrow, can give rise to red blood cells, white blood cells and platelets, whereas mesenchymal stem cells (MSCs) are derived from the stroma and give rise to non-blood forming cells and tissues. - Human embryonic stem cells (hESCs): Derived from embryos, these include stems cell lines, aborted embryos or from miscarriages, unused in vitro fertilized embryos and cloned embryos. There are currently no clinically approved treatments for embryonic stem cells. - Inducible pluripotent stem cell (iPSCs): These are stem cells generated in the laboratory by reprogramming adult cells that have already differentiated into specific cells, such as liver cells. They are used either for research purposes (e.g., experimental medicine testing toxicity of new drugs) or are under research for potential future clinical use.

Read the full report: https://www.reportlinker.com/p05835679/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/highs-and-lows-of-stem-cell-therapies-off--the-shelf-solutions-300982411.html

SOURCE Reportlinker

See the original post here:
Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions - P&T Community

Skin Stem Cells Comments Off on Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions – P&T Community | January 7th, 2020

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global amniotic membrane market since 2019 and the market is poised to grow by USD 1.48 billion during 2020-2024, progressing at a CAGR of more than 13% during the forecast period. Request a free sample report

Read the 145-page report with TOC on Amniotic Membrane Market Analysis Report by Geography (Asia, Europe, North America, and ROW), Type (Cryopreserved amniotic membrane and Dehydrated amniotic membrane), and the Segment Forecasts, 2020-2024.

https://www.technavio.com/report/amniotic-membrane-market-industry-analysis

The market is driven by the rising demand for biocompatible scaffolds. In addition, the rise in the development of new applications through research is anticipated to boost the growth of the amniotic membrane market.

The rising need for naturally derived materials in tissue scaffolding is increasing the demand for amniotic membranes. This is due to the specialized structure of amniotic membranes that exhibit high biological viability, making them ideal for creating bio-scaffolds. Moreover, the epithelial cells in amniotic membranes have the advantages of stem cells which provide a native environment of cell seeding. Bio-scaffolds are widely used in regenerative therapies for the treatment of bone, cartilage, skin, vascular tissues, and skeletal muscles. With growing geriatric population, the demand for such orthopaedic regenerative therapies is expected to increase significantly during the forecast period. This will have a positive impact on the demand for amniotic membranes.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Amniotic Membrane Market Companies:

Celularity Inc.

Celularity Inc. operates its business through the Unified Business Segment. BIOVANCE is the key offering of the company. It offers a decellularized, dehydrated human amniotic membrane allograft that contains natural extracellular matrix (ECM) that helps in wound regeneration and tissue restoration.

Human Regenerative Technologies LLC

Human Regenerative Technologies LLC operates the business across segments such as Flowable and Membrane. HydraTek amniotic membrane products, is the key offering of the company. It includes thin and thick dehydrated amniotic membranes used in covering and protecting the recipient's tissue.

Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corp. operates its business across segments such as Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers a wide range of amniotic membrane products. Some of the key offerings include AmnioExcel Amniotic Allograft Membrane, BioDDryFlex Amniotic Tissue Membrane, BioDOptix Amniotic Extracellular Membrane, and Integra BioFix Amniotic Membrane Allograft.

Katena Products Inc.

Katena Products Inc. operates the business across segments such as Instruments, Biologics, Plugs, Lenses, Devices, and Blink Medical. Amniotic Membrane Surgical and Amniotic Membrane Clinic are some of the key offerings of the company.

MiMedx Group Inc.

MiMedx Group Inc. operates the business in the Regenerative biomaterial products and bioimplants segment. The company offers a wide range of amniotic membrane products. AmnioFix, EpiFix, and EpiBurn are the key offerings of the company.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Amniotic Membrane Type Outlook (Revenue, USD Billion, 2020 - 2024)

Amniotic Membrane Regional Outlook (Revenue, USD Billion, 2020 - 2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare include:

Global Extracorporeal Membrane Oxygenation Machines Market Global extracorporeal membrane oxygenation machines market by geography (Asia, Europe, North America, and ROW) and modality (veno-venous and arterio-venous; and veno-arterial).

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Global Duchenne muscular dystrophy (DMD) therapeutics market by type (biologics and small molecules) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com

Here is the original post:
Global Amniotic Membrane Market 2020-2024 | Evolving Opportunities with Celularity Inc. and Human Regenerative Technologies LLC | Technavio - Business...

Skin Stem Cells Comments Off on Global Amniotic Membrane Market 2020-2024 | Evolving Opportunities with Celularity Inc. and Human Regenerative Technologies LLC | Technavio – Business… | January 7th, 2020